查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1497676

癌症生物標記市場：按生物標記類型、癌症類型、技術、應用、最終用戶 - 2024-2030 年全球預測

Cancer Biomarkers Market by Biomarker Type (Genetic, Protein), Cancer Type (Blood Cancer, Breast Cancer, Colorectal Cancer), Technology, Application, End User - Global Forecast 2024-2030
出版日期: | 出版商: 360iResearch | 英文 197 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

癌症生物標記市場規模預計2023年為283.1億美元，2024年達到312.3億美元，預計2030年將達到577.5億美元，複合年成長率為10.71%。

癌症生物標記是可以在身體部位（例如血液或組織）中測量的物質或過程，可以幫助檢測體內是否有癌症。蛋白質、基因突變或其他分子顯示身體可能正在對抗癌症。癌症生物標記的使用不斷擴大，主要是由於技術進步提高了這些測試的準確性和速度。此外，人們對個人化醫療的認知不斷提高，透過為每位患者提供量身定做的治療來改善治療結果，從而擴大了癌症生物標記的應用。然而，測試中的假陽性或假陰性可能導致錯誤的治療決策，並可能對市場成長構成挑戰。然而，目前難以早期檢測的癌症類型（例如胰腺癌和卵巢癌）的生物標記的開拓有可能擴大市場擴張的範圍。此外，將生物標記與數位健康資訊系統結合有可能增強患者監測和持續治療協調。

主要市場統計
基準年[2023] 283.1億美元
預測年份 [2024] 312.3億美元
預測年份 [2030] 577.5億美元
複合年成長率（%） 10.71%

區域洞察

在美洲，強大的醫療基礎設施以及對癌症篩檢和早期檢測的高度認知正在推動對癌症生物標記的需求。該地區，尤其是美國，是許多致力於開發新生物標記並將其商業化的大型生物技術和醫療保健公司的所在地。該市場從政府的支持措施和研發方面的大量投資中受益匪淺。由於西歐完善的醫療保健系統以及中東和非洲國家政府對癌症研究的支持不斷增加，EMEA（歐洲、中東和非洲）地區也是癌症生物標記的重要市場。由於醫療成本上升和癌症盛行率增加，亞太地區癌症生物標記領域呈現快速成長。中國、日本和印度等國家正大力投資醫療基礎設施和研究，推動成長。此外，這些經濟體的中產階級人口不斷成長，為實施先進的醫療保健解決方案（包括癌症生物標記）創造了巨大的機會。

FPNV定位矩陣

FPNV 定位矩陣對於評估供應商在癌症生物標記市場的定位至關重要。此矩陣提供了對供應商的全面評估，並檢驗了與業務策略和產品滿意度相關的關鍵指標。這種詳細的評估使用戶能夠根據自己的要求做出明智的決定。根據評估結果，供應商被分為代表其成功程度的四個像限：前沿（F）、探路者（P）、利基（N）和重要（V）。

市場佔有率分析

市場佔有率分析是一種綜合工具，可對癌症生物標記市場供應商的現狀進行深入而詳細的評估。透過仔細比較和分析供應商的貢獻，您可以更深入地了解每個供應商的績效以及他們在爭奪市場佔有率時面臨的挑戰。這些貢獻包括整體收益、客戶群和其他重要指標。此外，該分析還提供了對該領域競爭性質的寶貴見解，包括累積研究期、片段化優勢和合併特徵等因素。有了這些詳細資訊，供應商可以做出更明智的決策並製定有效的策略，以在市場競爭中保持領先地位。

策略分析與建議

策略分析對於尋求在全球市場站穩腳跟的組織至關重要。對目前在癌症生物標記市場中的地位進行全面評估，使公司能夠做出符合其長期願望的明智決策。此關鍵評估涉及對組織的資源、能力和整體績效進行徹底分析，以確定核心優勢和需要改進的領域。

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 人群中癌症盛行率增加
      • 加大早期癌症檢測的強度和宣傳活動
      • 擴大醫療基礎設施和醫療支出
    • 抑制因素
      • 研發成本高
    • 機會
      • 用於檢測惡性肝癌的更好生物標記的出現
      • 積極的研究活動旨在引入新的生物標記以早期檢測肺癌
    • 任務
      • 複雜且嚴格的監管合規
  • 市場區隔分析
    • 生物標記的類型：蛋白質生物標記物可效用透過血液和組織中所含的蛋白質檢測癌症的存在
    • 應用：診斷中優先選擇生物標記以進行早期檢測，以改善患者的治療結果
  • 市場擾動分析
  • 波特五力分析
  • 價值鍊和關鍵路徑分析
  • 價格分析
  • 技術分析
  • 專利分析
  • 貿易分析
  • 法規結構分析

第6章按生物標記類型分類的癌症生物標記市場

  • 遺傳上
  • 蛋白質

第 7 章按癌症類型分類的癌症生物標記市場

  • 血癌
  • 乳癌
  • 大腸直腸癌
  • 肺癌
  • 卵巢癌
  • 攝護腺癌
  • 皮膚癌
  • 胃癌

第8章癌症生物標記市場：依技術分類

  • 生物資訊學
  • 細胞遺傳學
  • 成像技術
  • 免疫學測試
  • 體學技術

第9章癌症生物標記市場：依應用分類

  • 診斷
  • 藥物發現與開發
  • 預言
  • 風險評估

第 10 章癌症生物標記市場：按最終用戶分類

  • 學術/癌症研究中心
  • 醫院
  • 專業中心

第11章美洲癌症生物標記市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第12章亞太地區癌症生物標記市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第13章歐洲、中東和非洲的癌症生物標記市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第14章競爭格局

  • 2023 年市場佔有率分析
  • FPNV 定位矩陣，2023
  • 競爭情境分析
    • Chromacord 與喬治亞醫學院結成策略聯盟，加強 NSCLC 診斷能力
    • 晶泰科技與CK Life Sciences加強人工智慧合作，打造下一代癌症診斷
    • 提高癌症治療的準確性：FDA啟動試驗計畫來規範伴同性藥物的伴隨診斷測試
  • 戰略分析和建議

第15章競爭組合

  • 主要企業簡介
  • 主要產品系列
Product Code: MRR-437517DB6E4D

[197 Pages Report] The Cancer Biomarkers Market size was estimated at USD 28.31 billion in 2023 and expected to reach USD 31.23 billion in 2024, at a CAGR 10.71% to reach USD 57.75 billion by 2030.

Cancer biomarkers are substances or processes that can be measured in parts of the body, such as blood or tissue, and help to detect the presence of cancer in the body. They can be proteins, genetic mutations, or other molecules that indicate the body may be fighting cancer. The use of cancer biomarkers is expanding primarily due to advancements in technology, which improve the accuracy and speed of these tests. Moreover, growing awareness of personalized medicine, which tailors treatment to individual patients and improves outcomes, has increased the applications of cancer biomarkers. However, false positives or negatives in tests, which can lead to incorrect treatment decisions, may challenge the market growth. Nevertheless, developing biomarkers for types of cancers that are currently hard to detect early, such as pancreatic or ovarian cancer, may increase the scope of market expansion. Additionally, integrating biomarkers with digital health information systems could enhance patient monitoring and ongoing treatment adjustments.

KEY MARKET STATISTICS
Base Year [2023] USD 28.31 billion
Estimated Year [2024] USD 31.23 billion
Forecast Year [2030] USD 57.75 billion
CAGR (%) 10.71%

Regional Insights

In the Americas, robust healthcare infrastructure and a high level of awareness about cancer screening and early detection drive the demand for cancer biomarkers. The region, especially the United States, is also home to numerous leading biotechnology and healthcare companies engaged in developing and commercializing new biomarkers. This marketplace benefits significantly from supportive government initiatives and substantial investment in research and development. EMEA also presents a substantial market for cancer biomarkers, supported by well-established healthcare systems in Western Europe and increasing government support for cancer research across the Middle Eastern and African countries. The Asia Pacific region showcases rapid growth in the cancer biomarkers field due to rising healthcare spending and the increasing prevalence of cancer. Countries such as China, Japan, and India are investing heavily in healthcare infrastructure and research, facilitating growth. Additionally, the expanding middle-class populations in these economies present a significant opportunity for the adoption of advanced healthcare solutions, including cancer biomarkers.

Market Insights

  • Market Dynamics

The market dynamics represent an ever-changing landscape of the Cancer Biomarkers Market by providing actionable insights into factors, including supply and demand levels. Accounting for these factors helps design strategies, make investments, and formulate developments to capitalize on future opportunities. In addition, these factors assist in avoiding potential pitfalls related to political, geographical, technical, social, and economic conditions, highlighting consumer behaviors and influencing manufacturing costs and purchasing decisions.

    • Market Drivers
      • Increasing prevalence of cancer disorders among population
      • Rising initiatives and awareness campaigns for early cancer detection
      • Growing healthcare infrastructure and healthcare spending
    • Market Restraints
      • High costs associated with research and development
    • Market Opportunities
      • Emergence of better biomarkers for detection of aggressive liver cancer
      • Robust research activities to introduce new biomarkers for early detection of lung cancer
    • Market Challenges
      • Complex and stringent regulatory compliances
  • Market Segmentation Analysis
    • Biomarker Type: Usability of protein biomarkers in detecting the presence of cancer through proteins found in blood or tissue
    • Application: Preferences for biomarkers in diagnostic for early-stage detection to improve treatment outcomes for patients
  • Market Disruption Analysis
  • Porter's Five Forces Analysis
  • Value Chain & Critical Path Analysis
  • Pricing Analysis
  • Technology Analysis
  • Patent Analysis
  • Trade Analysis
  • Regulatory Framework Analysis

FPNV Positioning Matrix

The FPNV positioning matrix is essential in evaluating the market positioning of the vendors in the Cancer Biomarkers Market. This matrix offers a comprehensive assessment of vendors, examining critical metrics related to business strategy and product satisfaction. This in-depth assessment empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success, namely Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The market share analysis is a comprehensive tool that provides an insightful and in-depth assessment of the current state of vendors in the Cancer Biomarkers Market. By meticulously comparing and analyzing vendor contributions, companies are offered a greater understanding of their performance and the challenges they face when competing for market share. These contributions include overall revenue, customer base, and other vital metrics. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With these illustrative details, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Recent Developments

Strategic Collaboration between ChromaCode and Medical College of Georgia to Enhance NSCLC Diagnostic Capabilities

ChromaCode, Inc. and the Department of Pathology at the Medical College of Georgia have announced a partnership aimed at evaluating the performance of ChromaCode's innovative HDPCR assay for non-small cell lung cancer (NSCLC). This assay, endorsed for its comprehensive coverage of clinically relevant variants by the National Comprehensive Cancer Network, delivers rapid results with a 4-hour workflow and utilizes cloud-based analytics for quick interpretation. [Published On: 2024-03-20]

Enhanced AI Collaboration Between XtalPi and CK Life Sciences for Next-Generation Cancer Diagnostics

China-based XtalPi and CK Life Sciences are intensifying their joint efforts to utilize artificial intelligence (AI) to develop miRNA-based molecular diagnostic models tailored for postoperative cancer care. This collaboration aims to refine prognostic risk predictions by analyzing anonymized clinical data and biomarker information sourced from both cancer patients and healthy individuals within CK's extensive database. [Published On: 2023-11-06]

Enhancing Precision in Cancer Treatment: FDA Initiates Pilot Program to Regulate Companion Diagnostic Tests for Oncology Drugs

The U.S. Food and Drug Administration (FDA) has introduced a pivotal pilot program focused on refining the integration of specific oncology drugs with their corresponding in-vitro diagnostic tests. This initiative primarily addresses the critical use of laboratory-developed tests (LDTs), which have yet to undergo the FDA's extensive review for safety or effectiveness. The program aims to establish and make public the minimum performance characteristics necessary for diagnostic tests utilized in clinical trials. [Published On: 2023-06-21]

Strategy Analysis & Recommendation

The strategic analysis is essential for organizations seeking a solid foothold in the global marketplace. Companies are better positioned to make informed decisions that align with their long-term aspirations by thoroughly evaluating their current standing in the Cancer Biomarkers Market. This critical assessment involves a thorough analysis of the organization's resources, capabilities, and overall performance to identify its core strengths and areas for improvement.

Key Company Profiles

The report delves into recent significant developments in the Cancer Biomarkers Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories Inc., Agilent Technologies, Inc., ASURAGEN, INC., Bio-Rad Laboratories, Inc., bioMerieux SA, Bristol-Myers Squibb Company, Bruker Corporation, Charles River Laboratories International, Inc., Enzo Biochem, Inc., Epigenomics AG, Eurofins Scientific SE, Exact Sciences Corporation, F. Hoffmann-La Roche Ltd., GE HealthCare Technologies Inc., Hologic, Inc., Illumina, Inc., Merck KGaA, Myriad Genetics, Inc., PerkinElmer, Inc., Pfizer Inc., QIAGEN N.V, Quest Diagnostics Incorporated, Siemens Healthcare GmbH, Sysmex Corporation, and Thermo Fisher Scientific Inc..

Market Segmentation & Coverage

This research report categorizes the Cancer Biomarkers Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Biomarker Type
    • Genetic
    • Protein
  • Cancer Type
    • Blood Cancer
    • Breast Cancer
    • Colorectal Cancer
    • Lung Cancer
    • Ovarian Cancer
    • Prostate Cancer
    • Skin Cancer
    • Stomach Cancer
  • Technology
    • Bioinformatics
    • Cytogenetics
    • Imaging Technology
    • Immunoassays
    • OMICS Technology
  • Application
    • Diagnostics
    • Drug Discovery & Development
    • Prognostics
    • Risk Assessment
  • End User
    • Academic & Cancer Research Centers
    • Hospitals
    • Speciality Centers
  • Region
    • Americas
      • Argentina
      • Brazil
      • Canada
      • Mexico
      • United States
        • California
        • Florida
        • Illinois
        • New York
        • Ohio
        • Pennsylvania
        • Texas
    • Asia-Pacific
      • Australia
      • China
      • India
      • Indonesia
      • Japan
      • Malaysia
      • Philippines
      • Singapore
      • South Korea
      • Taiwan
      • Thailand
      • Vietnam
    • Europe, Middle East & Africa
      • Denmark
      • Egypt
      • Finland
      • France
      • Germany
      • Israel
      • Italy
      • Netherlands
      • Nigeria
      • Norway
      • Poland
      • Qatar
      • Russia
      • Saudi Arabia
      • South Africa
      • Spain
      • Sweden
      • Switzerland
      • Turkey
      • United Arab Emirates
      • United Kingdom

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Increasing prevalence of cancer disorders among population
      • 5.1.1.2. Rising initiatives and awareness campaigns for early cancer detection
      • 5.1.1.3. Growing healthcare infrastructure and healthcare spending
    • 5.1.2. Restraints
      • 5.1.2.1. High costs associated with research and development
    • 5.1.3. Opportunities
      • 5.1.3.1. Emergence of better biomarkers for detection of aggressive liver cancer
      • 5.1.3.2. Robust research activities to introduce new biomarkers for early detection of lung cancer
    • 5.1.4. Challenges
      • 5.1.4.1. Complex and stringent regulatory compliances
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Biomarker Type: Usability of protein biomarkers in detecting the presence of cancer through proteins found in blood or tissue
    • 5.2.2. Application: Preferences for biomarkers in diagnostic for early-stage detection to improve treatment outcomes for patients
  • 5.3. Market Disruption Analysis
  • 5.4. Porter's Five Forces Analysis
    • 5.4.1. Threat of New Entrants
    • 5.4.2. Threat of Substitutes
    • 5.4.3. Bargaining Power of Customers
    • 5.4.4. Bargaining Power of Suppliers
    • 5.4.5. Industry Rivalry
  • 5.5. Value Chain & Critical Path Analysis
  • 5.6. Pricing Analysis
  • 5.7. Technology Analysis
  • 5.8. Patent Analysis
  • 5.9. Trade Analysis
  • 5.10. Regulatory Framework Analysis

6. Cancer Biomarkers Market, by Biomarker Type

  • 6.1. Introduction
  • 6.2. Genetic
  • 6.3. Protein

7. Cancer Biomarkers Market, by Cancer Type

  • 7.1. Introduction
  • 7.2. Blood Cancer
  • 7.3. Breast Cancer
  • 7.4. Colorectal Cancer
  • 7.5. Lung Cancer
  • 7.6. Ovarian Cancer
  • 7.7. Prostate Cancer
  • 7.8. Skin Cancer
  • 7.9. Stomach Cancer

8. Cancer Biomarkers Market, by Technology

  • 8.1. Introduction
  • 8.2. Bioinformatics
  • 8.3. Cytogenetics
  • 8.4. Imaging Technology
  • 8.5. Immunoassays
  • 8.6. OMICS Technology

9. Cancer Biomarkers Market, by Application

  • 9.1. Introduction
  • 9.2. Diagnostics
  • 9.3. Drug Discovery & Development
  • 9.4. Prognostics
  • 9.5. Risk Assessment

10. Cancer Biomarkers Market, by End User

  • 10.1. Introduction
  • 10.2. Academic & Cancer Research Centers
  • 10.3. Hospitals
  • 10.4. Speciality Centers

11. Americas Cancer Biomarkers Market

  • 11.1. Introduction
  • 11.2. Argentina
  • 11.3. Brazil
  • 11.4. Canada
  • 11.5. Mexico
  • 11.6. United States

12. Asia-Pacific Cancer Biomarkers Market

  • 12.1. Introduction
  • 12.2. Australia
  • 12.3. China
  • 12.4. India
  • 12.5. Indonesia
  • 12.6. Japan
  • 12.7. Malaysia
  • 12.8. Philippines
  • 12.9. Singapore
  • 12.10. South Korea
  • 12.11. Taiwan
  • 12.12. Thailand
  • 12.13. Vietnam

13. Europe, Middle East & Africa Cancer Biomarkers Market

  • 13.1. Introduction
  • 13.2. Denmark
  • 13.3. Egypt
  • 13.4. Finland
  • 13.5. France
  • 13.6. Germany
  • 13.7. Israel
  • 13.8. Italy
  • 13.9. Netherlands
  • 13.10. Nigeria
  • 13.11. Norway
  • 13.12. Poland
  • 13.13. Qatar
  • 13.14. Russia
  • 13.15. Saudi Arabia
  • 13.16. South Africa
  • 13.17. Spain
  • 13.18. Sweden
  • 13.19. Switzerland
  • 13.20. Turkey
  • 13.21. United Arab Emirates
  • 13.22. United Kingdom

14. Competitive Landscape

  • 14.1. Market Share Analysis, 2023
  • 14.2. FPNV Positioning Matrix, 2023
  • 14.3. Competitive Scenario Analysis
    • 14.3.1. Strategic Collaboration between ChromaCode and Medical College of Georgia to Enhance NSCLC Diagnostic Capabilities
    • 14.3.2. Enhanced AI Collaboration Between XtalPi and CK Life Sciences for Next-Generation Cancer Diagnostics
    • 14.3.3. Enhancing Precision in Cancer Treatment: FDA Initiates Pilot Program to Regulate Companion Diagnostic Tests for Oncology Drugs
  • 14.4. Strategy Analysis & Recommendation

15. Competitive Portfolio

  • 15.1. Key Company Profiles
  • 15.2. Key Product Portfolio

LIST OF FIGURES

  • FIGURE 1. CANCER BIOMARKERS MARKET RESEARCH PROCESS
  • FIGURE 2. CANCER BIOMARKERS MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL CANCER BIOMARKERS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL CANCER BIOMARKERS MARKET SIZE, BY REGION, 2023 VS 2030 (%)
  • FIGURE 5. GLOBAL CANCER BIOMARKERS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. CANCER BIOMARKERS MARKET DYNAMICS
  • FIGURE 7. GLOBAL CANCER BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2023 VS 2030 (%)
  • FIGURE 8. GLOBAL CANCER BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 9. GLOBAL CANCER BIOMARKERS MARKET SIZE, BY CANCER TYPE, 2023 VS 2030 (%)
  • FIGURE 10. GLOBAL CANCER BIOMARKERS MARKET SIZE, BY CANCER TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 11. GLOBAL CANCER BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2023 VS 2030 (%)
  • FIGURE 12. GLOBAL CANCER BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 13. GLOBAL CANCER BIOMARKERS MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
  • FIGURE 14. GLOBAL CANCER BIOMARKERS MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 15. GLOBAL CANCER BIOMARKERS MARKET SIZE, BY END USER, 2023 VS 2030 (%)
  • FIGURE 16. GLOBAL CANCER BIOMARKERS MARKET SIZE, BY END USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 17. AMERICAS CANCER BIOMARKERS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 18. AMERICAS CANCER BIOMARKERS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 19. UNITED STATES CANCER BIOMARKERS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 20. UNITED STATES CANCER BIOMARKERS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 21. ASIA-PACIFIC CANCER BIOMARKERS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 22. ASIA-PACIFIC CANCER BIOMARKERS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 23. EUROPE, MIDDLE EAST & AFRICA CANCER BIOMARKERS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 24. EUROPE, MIDDLE EAST & AFRICA CANCER BIOMARKERS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 25. CANCER BIOMARKERS MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 26. CANCER BIOMARKERS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. CANCER BIOMARKERS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL CANCER BIOMARKERS MARKET SIZE, 2018-2023 (USD MILLION)
  • TABLE 4. GLOBAL CANCER BIOMARKERS MARKET SIZE, 2024-2030 (USD MILLION)
  • TABLE 5. GLOBAL CANCER BIOMARKERS MARKET SIZE, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 6. GLOBAL CANCER BIOMARKERS MARKET SIZE, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 7. GLOBAL CANCER BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2018-2023 (USD MILLION)
  • TABLE 8. GLOBAL CANCER BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2024-2030 (USD MILLION)
  • TABLE 9. GLOBAL CANCER BIOMARKERS MARKET SIZE, BY GENETIC, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 10. GLOBAL CANCER BIOMARKERS MARKET SIZE, BY GENETIC, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 11. GLOBAL CANCER BIOMARKERS MARKET SIZE, BY PROTEIN, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 12. GLOBAL CANCER BIOMARKERS MARKET SIZE, BY PROTEIN, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 13. GLOBAL CANCER BIOMARKERS MARKET SIZE, BY CANCER TYPE, 2018-2023 (USD MILLION)
  • TABLE 14. GLOBAL CANCER BIOMARKERS MARKET SIZE, BY CANCER TYPE, 2024-2030 (USD MILLION)
  • TABLE 15. GLOBAL CANCER BIOMARKERS MARKET SIZE, BY BLOOD CANCER, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 16. GLOBAL CANCER BIOMARKERS MARKET SIZE, BY BLOOD CANCER, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 17. GLOBAL CANCER BIOMARKERS MARKET SIZE, BY BREAST CANCER, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 18. GLOBAL CANCER BIOMARKERS MARKET SIZE, BY BREAST CANCER, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 19. GLOBAL CANCER BIOMARKERS MARKET SIZE, BY COLORECTAL CANCER, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 20. GLOBAL CANCER BIOMARKERS MARKET SIZE, BY COLORECTAL CANCER, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 21. GLOBAL CANCER BIOMARKERS MARKET SIZE, BY LUNG CANCER, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 22. GLOBAL CANCER BIOMARKERS MARKET SIZE, BY LUNG CANCER, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 23. GLOBAL CANCER BIOMARKERS MARKET SIZE, BY OVARIAN CANCER, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 24. GLOBAL CANCER BIOMARKERS MARKET SIZE, BY OVARIAN CANCER, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 25. GLOBAL CANCER BIOMARKERS MARKET SIZE, BY PROSTATE CANCER, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 26. GLOBAL CANCER BIOMARKERS MARKET SIZE, BY PROSTATE CANCER, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 27. GLOBAL CANCER BIOMARKERS MARKET SIZE, BY SKIN CANCER, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 28. GLOBAL CANCER BIOMARKERS MARKET SIZE, BY SKIN CANCER, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 29. GLOBAL CANCER BIOMARKERS MARKET SIZE, BY STOMACH CANCER, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 30. GLOBAL CANCER BIOMARKERS MARKET SIZE, BY STOMACH CANCER, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 31. GLOBAL CANCER BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 32. GLOBAL CANCER BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 33. GLOBAL CANCER BIOMARKERS MARKET SIZE, BY BIOINFORMATICS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 34. GLOBAL CANCER BIOMARKERS MARKET SIZE, BY BIOINFORMATICS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 35. GLOBAL CANCER BIOMARKERS MARKET SIZE, BY CYTOGENETICS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 36. GLOBAL CANCER BIOMARKERS MARKET SIZE, BY CYTOGENETICS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 37. GLOBAL CANCER BIOMARKERS MARKET SIZE, BY IMAGING TECHNOLOGY, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 38. GLOBAL CANCER BIOMARKERS MARKET SIZE, BY IMAGING TECHNOLOGY, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 39. GLOBAL CANCER BIOMARKERS MARKET SIZE, BY IMMUNOASSAYS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 40. GLOBAL CANCER BIOMARKERS MARKET SIZE, BY IMMUNOASSAYS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 41. GLOBAL CANCER BIOMARKERS MARKET SIZE, BY OMICS TECHNOLOGY, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 42. GLOBAL CANCER BIOMARKERS MARKET SIZE, BY OMICS TECHNOLOGY, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 43. GLOBAL CANCER BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 44. GLOBAL CANCER BIOMARKERS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 45. GLOBAL CANCER BIOMARKERS MARKET SIZE, BY DIAGNOSTICS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 46. GLOBAL CANCER BIOMARKERS MARKET SIZE, BY DIAGNOSTICS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 47. GLOBAL CANCER BIOMARKERS MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 48. GLOBAL CANCER BIOMARKERS MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 49. GLOBAL CANCER BIOMARKERS MARKET SIZE, BY PROGNOSTICS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 50. GLOBAL CANCER BIOMARKERS MARKET SIZE, BY PROGNOSTICS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 51. GLOBAL CANCER BIOMARKERS MARKET SIZE, BY RISK ASSESSMENT, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 52. GLOBAL CANCER BIOMARKERS MARKET SIZE, BY RISK ASSESSMENT, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 53. GLOBAL CANCER BIOMARKERS MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 54. GLOBAL CANCER BIOMARKERS MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 55. GLOBAL CANCER BIOMARKERS MARKET SIZE, BY ACADEMIC & CANCER RESEARCH CENTERS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 56. GLOBAL CANCER BIOMARKERS MARKET SIZE, BY ACADEMIC & CANCER RESEARCH CENTERS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 57. GLOBAL CANCER BIOMARKERS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 58. GLOBAL CANCER BIOMARKERS MARKET SIZE, BY HOSPITALS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 59. GLOBAL CANCER BIOMARKERS MARKET SIZE, BY SPECIALITY CENTERS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 60. GLOBAL CANCER BIOMARKERS MARKET SIZE, BY SPECIALITY CENTERS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 61. AMERICAS CANCER BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2018-2023 (USD MILLION)
  • TABLE 62. AMERICAS CANCER BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2024-2030 (USD MILLION)
  • TABLE 63. AMERICAS CANCER BIOMARKERS MARKET SIZE, BY CANCER TYPE, 2018-2023 (USD MILLION)
  • TABLE 64. AMERICAS CANCER BIOMARKERS MARKET SIZE, BY CANCER TYPE, 2024-2030 (USD MILLION)
  • TABLE 65. AMERICAS CANCER BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 66. AMERICAS CANCER BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 67. AMERICAS CANCER BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 68. AMERICAS CANCER BIOMARKERS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 69. AMERICAS CANCER BIOMARKERS MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 70. AMERICAS CANCER BIOMARKERS MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 71. AMERICAS CANCER BIOMARKERS MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
  • TABLE 72. AMERICAS CANCER BIOMARKERS MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
  • TABLE 73. ARGENTINA CANCER BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2018-2023 (USD MILLION)
  • TABLE 74. ARGENTINA CANCER BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2024-2030 (USD MILLION)
  • TABLE 75. ARGENTINA CANCER BIOMARKERS MARKET SIZE, BY CANCER TYPE, 2018-2023 (USD MILLION)
  • TABLE 76. ARGENTINA CANCER BIOMARKERS MARKET SIZE, BY CANCER TYPE, 2024-2030 (USD MILLION)
  • TABLE 77. ARGENTINA CANCER BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 78. ARGENTINA CANCER BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 79. ARGENTINA CANCER BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 80. ARGENTINA CANCER BIOMARKERS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 81. ARGENTINA CANCER BIOMARKERS MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 82. ARGENTINA CANCER BIOMARKERS MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 83. BRAZIL CANCER BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2018-2023 (USD MILLION)
  • TABLE 84. BRAZIL CANCER BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2024-2030 (USD MILLION)
  • TABLE 85. BRAZIL CANCER BIOMARKERS MARKET SIZE, BY CANCER TYPE, 2018-2023 (USD MILLION)
  • TABLE 86. BRAZIL CANCER BIOMARKERS MARKET SIZE, BY CANCER TYPE, 2024-2030 (USD MILLION)
  • TABLE 87. BRAZIL CANCER BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 88. BRAZIL CANCER BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 89. BRAZIL CANCER BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 90. BRAZIL CANCER BIOMARKERS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 91. BRAZIL CANCER BIOMARKERS MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 92. BRAZIL CANCER BIOMARKERS MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 93. CANADA CANCER BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2018-2023 (USD MILLION)
  • TABLE 94. CANADA CANCER BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2024-2030 (USD MILLION)
  • TABLE 95. CANADA CANCER BIOMARKERS MARKET SIZE, BY CANCER TYPE, 2018-2023 (USD MILLION)
  • TABLE 96. CANADA CANCER BIOMARKERS MARKET SIZE, BY CANCER TYPE, 2024-2030 (USD MILLION)
  • TABLE 97. CANADA CANCER BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 98. CANADA CANCER BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 99. CANADA CANCER BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 100. CANADA CANCER BIOMARKERS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 101. CANADA CANCER BIOMARKERS MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 102. CANADA CANCER BIOMARKERS MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 103. MEXICO CANCER BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2018-2023 (USD MILLION)
  • TABLE 104. MEXICO CANCER BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2024-2030 (USD MILLION)
  • TABLE 105. MEXICO CANCER BIOMARKERS MARKET SIZE, BY CANCER TYPE, 2018-2023 (USD MILLION)
  • TABLE 106. MEXICO CANCER BIOMARKERS MARKET SIZE, BY CANCER TYPE, 2024-2030 (USD MILLION)
  • TABLE 107. MEXICO CANCER BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 108. MEXICO CANCER BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 109. MEXICO CANCER BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 110. MEXICO CANCER BIOMARKERS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 111. MEXICO CANCER BIOMARKERS MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 112. MEXICO CANCER BIOMARKERS MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 113. UNITED STATES CANCER BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2018-2023 (USD MILLION)
  • TABLE 114. UNITED STATES CANCER BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2024-2030 (USD MILLION)
  • TABLE 115. UNITED STATES CANCER BIOMARKERS MARKET SIZE, BY CANCER TYPE, 2018-2023 (USD MILLION)
  • TABLE 116. UNITED STATES CANCER BIOMARKERS MARKET SIZE, BY CANCER TYPE, 2024-2030 (USD MILLION)
  • TABLE 117. UNITED STATES CANCER BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 118. UNITED STATES CANCER BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 119. UNITED STATES CANCER BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 120. UNITED STATES CANCER BIOMARKERS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 121. UNITED STATES CANCER BIOMARKERS MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 122. UNITED STATES CANCER BIOMARKERS MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 123. UNITED STATES CANCER BIOMARKERS MARKET SIZE, BY STATE, 2018-2023 (USD MILLION)
  • TABLE 124. UNITED STATES CANCER BIOMARKERS MARKET SIZE, BY STATE, 2024-2030 (USD MILLION)
  • TABLE 125. ASIA-PACIFIC CANCER BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2018-2023 (USD MILLION)
  • TABLE 126. ASIA-PACIFIC CANCER BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2024-2030 (USD MILLION)
  • TABLE 127. ASIA-PACIFIC CANCER BIOMARKERS MARKET SIZE, BY CANCER TYPE, 2018-2023 (USD MILLION)
  • TABLE 128. ASIA-PACIFIC CANCER BIOMARKERS MARKET SIZE, BY CANCER TYPE, 2024-2030 (USD MILLION)
  • TABLE 129. ASIA-PACIFIC CANCER BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 130. ASIA-PACIFIC CANCER BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 131. ASIA-PACIFIC CANCER BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 132. ASIA-PACIFIC CANCER BIOMARKERS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 133. ASIA-PACIFIC CANCER BIOMARKERS MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 134. ASIA-PACIFIC CANCER BIOMARKERS MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 135. ASIA-PACIFIC CANCER BIOMARKERS MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
  • TABLE 136. ASIA-PACIFIC CANCER BIOMARKERS MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
  • TABLE 137. AUSTRALIA CANCER BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2018-2023 (USD MILLION)
  • TABLE 138. AUSTRALIA CANCER BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2024-2030 (USD MILLION)
  • TABLE 139. AUSTRALIA CANCER BIOMARKERS MARKET SIZE, BY CANCER TYPE, 2018-2023 (USD MILLION)
  • TABLE 140. AUSTRALIA CANCER BIOMARKERS MARKET SIZE, BY CANCER TYPE, 2024-2030 (USD MILLION)
  • TABLE 141. AUSTRALIA CANCER BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 142. AUSTRALIA CANCER BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 143. AUSTRALIA CANCER BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 144. AUSTRALIA CANCER BIOMARKERS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 145. AUSTRALIA CANCER BIOMARKERS MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 146. AUSTRALIA CANCER BIOMARKERS MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 147. CHINA CANCER BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2018-2023 (USD MILLION)
  • TABLE 148. CHINA CANCER BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2024-2030 (USD MILLION)
  • TABLE 149. CHINA CANCER BIOMARKERS MARKET SIZE, BY CANCER TYPE, 2018-2023 (USD MILLION)
  • TABLE 150. CHINA CANCER BIOMARKERS MARKET SIZE, BY CANCER TYPE, 2024-2030 (USD MILLION)
  • TABLE 151. CHINA CANCER BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 152. CHINA CANCER BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 153. CHINA CANCER BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 154. CHINA CANCER BIOMARKERS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 155. CHINA CANCER BIOMARKERS MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 156. CHINA CANCER BIOMARKERS MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 157. INDIA CANCER BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2018-2023 (USD MILLION)
  • TABLE 158. INDIA CANCER BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2024-2030 (USD MILLION)
  • TABLE 159. INDIA CANCER BIOMARKERS MARKET SIZE, BY CANCER TYPE, 2018-2023 (USD MILLION)
  • TABLE 160. INDIA CANCER BIOMARKERS MARKET SIZE, BY CANCER TYPE, 2024-2030 (USD MILLION)
  • TABLE 161. INDIA CANCER BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 162. INDIA CANCER BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 163. INDIA CANCER BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 164. INDIA CANCER BIOMARKERS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 165. INDIA CANCER BIOMARKERS MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 166. INDIA CANCER BIOMARKERS MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 167. INDONESIA CANCER BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2018-2023 (USD MILLION)
  • TABLE 168. INDONESIA CANCER BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2024-2030 (USD MILLION)
  • TABLE 169. INDONESIA CANCER BIOMARKERS MARKET SIZE, BY CANCER TYPE, 2018-2023 (USD MILLION)
  • TABLE 170. INDONESIA CANCER BIOMARKERS MARKET SIZE, BY CANCER TYPE, 2024-2030 (USD MILLION)
  • TABLE 171. INDONESIA CANCER BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 172. INDONESIA CANCER BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 173. INDONESIA CANCER BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 174. INDONESIA CANCER BIOMARKERS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 175. INDONESIA CANCER BIOMARKERS MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 176. INDONESIA CANCER BIOMARKERS MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 177. JAPAN CANCER BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2018-2023 (USD MILLION)
  • TABLE 178. JAPAN CANCER BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2024-2030 (USD MILLION)
  • TABLE 179. JAPAN CANCER BIOMARKERS MARKET SIZE, BY CANCER TYPE, 2018-2023 (USD MILLION)
  • TABLE 180. JAPAN CANCER BIOMARKERS MARKET SIZE, BY CANCER TYPE, 2024-2030 (USD MILLION)
  • TABLE 181. JAPAN CANCER BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 182. JAPAN CANCER BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 183. JAPAN CANCER BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 184. JAPAN CANCER BIOMARKERS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 185. JAPAN CANCER BIOMARKERS MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 186. JAPAN CANCER BIOMARKERS MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 187. MALAYSIA CANCER BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2018-2023 (USD MILLION)
  • TABLE 188. MALAYSIA CANCER BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2024-2030 (USD MILLION)
  • TABLE 189. MALAYSIA CANCER BIOMARKERS MARKET SIZE, BY CANCER TYPE, 2018-2023 (USD MILLION)
  • TABLE 190. MALAYSIA CANCER BIOMARKERS MARKET SIZE, BY CANCER TYPE, 2024-2030 (USD MILLION)
  • TABLE 191. MALAYSIA CANCER BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 192. MALAYSIA CANCER BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 193. MALAYSIA CANCER BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 194. MALAYSIA CANCER BIOMARKERS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 195. MALAYSIA CANCER BIOMARKERS MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 196. MALAYSIA CANCER BIOMARKERS MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 197. PHILIPPINES CANCER BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2018-2023 (USD MILLION)
  • TABLE 198. PHILIPPINES CANCER BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2024-2030 (USD MILLION)
  • TABLE 199. PHILIPPINES CANCER BIOMARKERS MARKET SIZE, BY CANCER TYPE, 2018-2023 (USD MILLION)
  • TABLE 200. PHILIPPINES CANCER BIOMARKERS MARKET SIZE, BY CANCER TYPE, 2024-2030 (USD MILLION)
  • TABLE 201. PHILIPPINES CANCER BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 202. PHILIPPINES CANCER BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 203. PHILIPPINES CANCER BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 204. PHILIPPINES CANCER BIOMARKERS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 205. PHILIPPINES CANCER BIOMARKERS MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 206. PHILIPPINES CANCER BIOMARKERS MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 207. SINGAPORE CANCER BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2018-2023 (USD MILLION)
  • TABLE 208. SINGAPORE CANCER BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2024-2030 (USD MILLION)
  • TABLE 209. SINGAPORE CANCER BIOMARKERS MARKET SIZE, BY CANCER TYPE, 2018-2023 (USD MILLION)
  • TABLE 210. SINGAPORE CANCER BIOMARKERS MARKET SIZE, BY CANCER TYPE, 2024-2030 (USD MILLION)
  • TABLE 211. SINGAPORE CANCER BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 212. SINGAPORE CANCER BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 213. SINGAPORE CANCER BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 214. SINGAPORE CANCER BIOMARKERS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 215. SINGAPORE CANCER BIOMARKERS MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 216. SINGAPORE CANCER BIOMARKERS MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 217. SOUTH KOREA CANCER BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2018-2023 (USD MILLION)
  • TABLE 218. SOUTH KOREA CANCER BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2024-2030 (USD MILLION)
  • TABLE 219. SOUTH KOREA CANCER BIOMARKERS MARKET SIZE, BY CANCER TYPE, 2018-2023 (USD MILLION)
  • TABLE 220. SOUTH KOREA CANCER BIOMARKERS MARKET SIZE, BY CANCER TYPE, 2024-2030 (USD MILLION)
  • TABLE 221. SOUTH KOREA CANCER BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 222. SOUTH KOREA CANCER BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 223. SOUTH KOREA CANCER BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 224. SOUTH KOREA CANCER BIOMARKERS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 225. SOUTH KOREA CANCER BIOMARKERS MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 226. SOUTH KOREA CANCER BIOMARKERS MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 227. TAIWAN CANCER BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2018-2023 (USD MILLION)
  • TABLE 228. TAIWAN CANCER BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2024-2030 (USD MILLION)
  • TABLE 229. TAIWAN CANCER BIOMARKERS MARKET SIZE, BY CANCER TYPE, 2018-2023 (USD MILLION)
  • TABLE 230. TAIWAN CANCER BIOMARKERS MARKET SIZE, BY CANCER TYPE, 2024-2030 (USD MILLION)
  • TABLE 231. TAIWAN CANCER BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 232. TAIWAN CANCER BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 233. TAIWAN CANCER BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 234. TAIWAN CANCER BIOMARKERS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 235. TAIWAN CANCER BIOMARKERS MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 236. TAIWAN CANCER BIOMARKERS MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 237. THAILAND CANCER BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2018-2023 (USD MILLION)
  • TABLE 238. THAILAND CANCER BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2024-2030 (USD MILLION)
  • TABLE 239. THAILAND CANCER BIOMARKERS MARKET SIZE, BY CANCER TYPE, 2018-2023 (USD MILLION)
  • TABLE 240. THAILAND CANCER BIOMARKERS MARKET SIZE, BY CANCER TYPE, 2024-2030 (USD MILLION)
  • TABLE 241. THAILAND CANCER BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 242. THAILAND CANCER BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 243. THAILAND CANCER BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 244. THAILAND CANCER BIOMARKERS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 245. THAILAND CANCER BIOMARKERS MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 246. THAILAND CANCER BIOMARKERS MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 247. VIETNAM CANCER BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2018-2023 (USD MILLION)
  • TABLE 248. VIETNAM CANCER BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2024-2030 (USD MILLION)
  • TABLE 249. VIETNAM CANCER BIOMARKERS MARKET SIZE, BY CANCER TYPE, 2018-2023 (USD MILLION)
  • TABLE 250. VIETNAM CANCER BIOMARKERS MARKET SIZE, BY CANCER TYPE, 2024-2030 (USD MILLION)
  • TABLE 251. VIETNAM CANCER BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 252. VIETNAM CANCER BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 253. VIETNAM CANCER BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 254. VIETNAM CANCER BIOMARKERS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 255. VIETNAM CANCER BIOMARKERS MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 256. VIETNAM CANCER BIOMARKERS MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 257. EUROPE, MIDDLE EAST & AFRICA CANCER BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2018-2023 (USD MILLION)
  • TABLE 258. EUROPE, MIDDLE EAST & AFRICA CANCER BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2024-2030 (USD MILLION)
  • TABLE 259. EUROPE, MIDDLE EAST & AFRICA CANCER BIOMARKERS MARKET SIZE, BY CANCER TYPE, 2018-2023 (USD MILLION)
  • TABLE 260. EUROPE, MIDDLE EAST & AFRICA CANCER BIOMARKERS MARKET SIZE, BY CANCER TYPE, 2024-2030 (USD MILLION)
  • TABLE 261. EUROPE, MIDDLE EAST & AFRICA CANCER BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 262. EUROPE, MIDDLE EAST & AFRICA CANCER BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 263. EUROPE, MIDDLE EAST & AFRICA CANCER BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 264. EUROPE, MIDDLE EAST & AFRICA CANCER BIOMARKERS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 265. EUROPE, MIDDLE EAST & AFRICA CANCER BIOMARKERS MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 266. EUROPE, MIDDLE EAST & AFRICA CANCER BIOMARKERS MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 267. EUROPE, MIDDLE EAST & AFRICA CANCER BIOMARKERS MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
  • TABLE 268. EUROPE, MIDDLE EAST & AFRICA CANCER BIOMARKERS MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
  • TABLE 269. DENMARK CANCER BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2018-2023 (USD MILLION)
  • TABLE 270. DENMARK CANCER BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2024-2030 (USD MILLION)
  • TABLE 271. DENMARK CANCER BIOMARKERS MARKET SIZE, BY CANCER TYPE, 2018-2023 (USD MILLION)
  • TABLE 272. DENMARK CANCER BIOMARKERS MARKET SIZE, BY CANCER TYPE, 2024-2030 (USD MILLION)
  • TABLE 273. DENMARK CANCER BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 274. DENMARK CANCER BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 275. DENMARK CANCER BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 276. DENMARK CANCER BIOMARKERS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 277. DENMARK CANCER BIOMARKERS MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 278. DENMARK CANCER BIOMARKERS MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 279. EGYPT CANCER BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2018-2023 (USD MILLION)
  • TABLE 280. EGYPT CANCER BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2024-2030 (USD MILLION)
  • TABLE 281. EGYPT CANCER BIOMARKERS MARKET SIZE, BY CANCER TYPE, 2018-2023 (USD MILLION)
  • TABLE 282. EGYPT CANCER BIOMARKERS MARKET SIZE, BY CANCER TYPE, 2024-2030 (USD MILLION)
  • TABLE 283. EGYPT CANCER BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 284. EGYPT CANCER BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 285. EGYPT CANCER BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 286. EGYPT CANCER BIOMARKERS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 287. EGYPT CANCER BIOMARKERS MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 288. EGYPT CANCER BIOMARKERS MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 289. FINLAND CANCER BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2018-2023 (USD MILLION)
  • TABLE 290. FINLAND CANCER BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2024-2030 (USD MILLION)
  • TABLE 291. FINLAND CANCER BIOMARKERS MARKET SIZE, BY CANCER TYPE, 2018-2023 (USD MILLION)
  • TABLE 292. FINLAND CANCER BIOMARKERS MARKET SIZE, BY CANCER TYPE, 2024-2030 (USD MILLION)
  • TABLE 293. FINLAND CANCER BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 294. FINLAND CANCER BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 295. FINLAND CANCER BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 296. FINLAND CANCER BIOMARKERS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 297. FINLAND CANCER BIOMARKERS MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 298. FINLAND CANCER BIOMARKERS MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 299. FRANCE CANCER BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2018-2023 (USD MILLION)
  • TABLE 300. FRANCE CANCER BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2024-2030 (USD MILLION)
  • TABLE 301. FRANCE CANCER BIOMARKERS MARKET SIZE, BY CANCER TYPE, 2018-2023 (USD MILLION)
  • TABLE 302. FRANCE CANCER BIOMARKERS MARKET SIZE, BY CANCER TYPE, 2024-2030 (USD MILLION)
  • TABLE 303. FRANCE CANCER BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 304. FRANCE CANCER BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 305. FRANCE CANCER BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 306. FRANCE CANCER BIOMARKERS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 307. FRANCE CANCER BIOMARKERS MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 308. FRANCE CANCER BIOMARKERS MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 309. GERMANY CANCER BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2018-2023 (USD MILLION)
  • TABLE 310. GERMANY CANCER BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2024-2030 (USD MILLION)
  • TABLE 311. GERMANY CANCER BIOMARKERS MARKET SIZE, BY CANCER TYPE, 2018-2023 (USD MILLION)
  • TABLE 312. GERMANY CANCER BIOMARKERS MARKET SIZE, BY CANCER TYPE, 2024-2030 (USD MILLION)
  • TABLE 313. GERMANY CANCER BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 314. GERMANY CANCER BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 315. GERMANY CANCER BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 316. GERMANY CANCER BIOMARKERS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 317. GERMANY CANCER BIOMARKERS MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 318. GERMANY CANCER BIOMARKERS MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 319. ISRAEL CANCER BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2018-2023 (USD MILLION)
  • TABLE 320. ISRAEL CANCER BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2024-2030 (USD MILLION)
  • TABLE 321. ISRAEL CANCER BIOMARKERS MARKET SIZE, BY CANCER TYPE, 2018-2023 (USD MILLION)
  • TABLE 322. ISRAEL CANCER BIOMARKERS MARKET SIZE, BY CANCER TYPE, 2024-2030 (USD MILLION)
  • TABLE 323. ISRAEL CANCER BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 324. ISRAEL CANCER BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 325. ISRAEL CANCER BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 326. ISRAEL CANCER BIOMARKERS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 327. ISRAEL CANCER BIOMARKERS MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 328. ISRAEL CANCER BIOMARKERS MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 329. ITALY CANCER BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2018-2023 (USD MILLION)
  • TABLE 330. ITALY CANCER BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2024-2030 (USD MILLION)
  • TABLE 331. ITALY CANCER BIOMARKERS MARKET SIZE, BY CANCER TYPE, 2018-2023 (USD MILLION)
  • TABLE 332. ITALY CANCER BIOMARKERS MARKET SIZE, BY CANCER TYPE, 2024-2030 (USD MILLION)
  • TABLE 333. ITALY CANCER BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 334. ITALY CANCER BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 335. ITALY CANCER BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 336. ITALY CANCER BIOMARKERS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 337. ITALY CANCER BIOMARKERS MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 338. ITALY CANCER BIOMARKERS MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 339. NETHERLANDS CANCER BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2018-2023 (USD MILLION)
  • TABLE 340. NETHERLANDS CANCER BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2024-2030 (USD MILLION)
  • TABLE 341. NETHERLANDS CANCER BIOMARKERS MARKET SIZE, BY CANCER TYPE, 2018-2023 (USD MILLION)
  • TABLE 342. NETHERLANDS CANCER BIOMARKERS MARKET SIZE, BY CANCER TYPE, 2024-2030 (USD MILLION)
  • TABLE 343. NETHERLANDS CANCER BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 344. NETHERLANDS CANCER BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 345. NETHERLANDS CANCER BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 346. NETHERLANDS CANCER BIOMARKERS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 347. NETHERLANDS CANCER BIOMARKERS MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 348. NETHERLANDS CANCER BIOMARKERS MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 349. NIGERIA CANCER BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2018-2023 (USD MILLION)
  • TABLE 350. NIGERIA CANCER BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2024-2030 (USD MILLION)
  • TABLE 351. NIGERIA CANCER BIOMARKERS MARKET SIZE, BY CANCER TYPE, 2018-2023 (USD MILLION)
  • TABLE 352. NIGERIA CANCER BIOMARKERS MARKET SIZE, BY CANCER TYPE, 2024-2030 (USD MILLION)
  • TABLE 353. NIGERIA CANCER BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 354. NIGERIA CANCER BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 355. NIGERIA CANCER BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 356. NIGERIA CANCER BIOMARKERS MARKET SIZE, BY APPLICATION, 2024-2030 (USD M